The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...

Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.

At the moment, anti-obesity medicines (AOMs) like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide) are not covered by Medicare and Medicaid simply for reducing body ...